A new pilot Medicaid program — GENEROUS — combines centralized pharmaceutical-coverage negotiations with most-favored-nation pricing in an effort to lower drug costs, but it has some limitations.

A virtual consultation was held on May 2 with medical specialists from South Africa, the United Kingdom, and Holland to discuss the potential link to two recent fatalities associated with the same ...

Blood transfusion before arrival at a hospital reduces mortality from traumatic hemorrhage and shock. Whether transfusion with whole blood is more beneficial than transfusion with blood components ...

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

In this first episode of a two-part Double Take miniseries on cardiovascular risk factors from the New England Journal of Medicine, five key drivers of cardiovascular disease are reviewed. The video ...

Vaccine hesitancy exists along a spectrum; most parents with hesitancy are motivated to protect their children but are often concerned about safety. Routine childhood vaccines recommended by the ...

Wheezing illnesses are a leading cause of hospitalization for preschool-age children and are frequently treated with antibiotics. Observational studies have shown more frequent isolation of three ...

Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...

A 50-year-old woman was admitted to the hospital because of vaginal bleeding and anemia. She had a history of fibroids and 1 ...

This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

In this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ...